Page last updated: 2024-08-26

sr141716 and exenatide

sr141716 has been researched along with exenatide in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (85.71)	29.6817
2010's	1 (14.29)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Lebovitz, H	1
Klein, HH; Meier, JJ; Schmidt, WE	1
Feinglos, MN; Green, JB	1
Aronne, LJ; Neff, LM	1
Barnett, A; Rahim, A; Samat, A	1
Seissler, J	1
Bahekar, R; Jain, MR; Joharapurkar, AA; Kshirsagar, SG; Patel, KN; Patel, V; Srivastava, BK	1

Reviews

5 review(s) available for sr141716 and exenatide

Article	Year
Diabetes: assessing the pipeline. Atherosclerosis. Supplements, 2006, Volume: 7, Issue:1 Topics: Adamantane; Alkanesulfonates; Amyloid; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exenatide; Glycine; Humans; Hypoglycemic Agents; Indoles; Islet Amyloid Polypeptide; Maleimides; Nitriles; Oxazoles; Peptides; Phenylpropionates; Piperidines; PPAR alpha; PPAR gamma; Protein Kinase C; Pyrazoles; Pyrrolidines; Receptor, Cannabinoid, CB1; Receptors, Glucagon; Rimonabant; Venoms; Vildagliptin	2006
[New concepts in the treatment of type 2 diabetes]. Der Internist, 2007, Volume: 48, Issue:7 Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Nitriles; Peptides; Piperidines; Pyrazines; Pyrazoles; Pyrrolidines; Rimonabant; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity. Current diabetes reports, 2007, Volume: 7, Issue:5 Topics: Appetite Depressants; Cannabinoid Receptor Antagonists; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Obesity; Peptides; Piperidines; Pyrazoles; Rimonabant; Venoms	2007
Pharmacotherapy for obesity. Current atherosclerosis reports, 2007, Volume: 9, Issue:6 Topics: Amyloid; Anti-Obesity Agents; Appetite Depressants; Body Weight; Chronic Disease; Comorbidity; Cyclobutanes; Exenatide; Gastrointestinal Hormones; Humans; Islet Amyloid Polypeptide; Lactones; Leptin; Metformin; Obesity; Orlistat; Peptides; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Venoms	2007
Pharmacotherapy for obesity in menopausal women. Menopause international, 2008, Volume: 14, Issue:2 Topics: Anti-Obesity Agents; Bariatric Surgery; Cyclobutanes; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Lactones; Menopause; Metformin; Obesity; Orlistat; Peptides; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Venoms	2008

Other Studies

2 other study(ies) available for sr141716 and exenatide

Article	Year
[Treatment of type 2 diabetes with new oral antihyperglycaemic drugs]. MMW Fortschritte der Medizin, 2008, May-01, Volume: 150, Issue:18 Topics: Administration, Oral; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Peptides; Piperidines; Pyrazoles; Rimonabant; Venoms	2008
Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice. Canadian journal of physiology and pharmacology, 2014, Volume: 92, Issue:12 Topics: Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Diet, High-Fat; Drug Synergism; Eating; Exenatide; Glucagon; Glucagon-Like Peptide 1; Insulin Resistance; Male; Mice, Inbred C57BL; Mice, Obese; Obesity; Peptides; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Venoms	2014

Article

Year

[Treatment of type 2 diabetes with new oral antihyperglycaemic drugs].

MMW Fortschritte der Medizin, 2008, May-01, Volume: 150, Issue:18

Topics: Administration, Oral; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Peptides; Piperidines; Pyrazoles; Rimonabant; Venoms

2008

Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.

Canadian journal of physiology and pharmacology, 2014, Volume: 92, Issue:12

Topics: Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Diet, High-Fat; Drug Synergism; Eating; Exenatide; Glucagon; Glucagon-Like Peptide 1; Insulin Resistance; Male; Mice, Inbred C57BL; Mice, Obese; Obesity; Peptides; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Venoms

2014